Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

NCT01197469 ↗

Phase 2 Completed 120 enrolled University of Dundee Chief Scientist Office of the Scottish Government · collab NHS Fife · collab NHS Tayside · collab

RandomizedSingle-groupDouble-blindTreatment

Summary

The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.

Timeline

Start: 2010-09
Primary completion: 2012-09
Completion: 2012-09

Publications

Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014 Apr;2(4):293-300. doi: 10.1016/S2213-2600(14)70013-X. Epub 2014 Mar 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tadalafil	Small molecule	10 mg	—

Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

Summary

Timeline

Publications

Drugs

Indications